drugset / Trial / NCT01533935

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

NCT01533935

Phase 3 Completed 291 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD.

Timeline

Start
2012-02
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Olodaterol Small molecule 5 ug Inhaled
Subject Tiotropium Other / unclassified 2.5 ug Inhaled
Subject Tiotropium Other / unclassified 5 ug Inhaled